Fayez Sarofim & Co
VRTX icon

Fayez Sarofim & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Fayez Sarofim & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.47M Hold
10,000
– – 0.01% 119
2025
Q4 		$4.53M Sell
10,000
-58
-0.6% -$25K 0.01% 125
2025
Q3 		$3.94M Sell
10,058
-300
-3% -$125K 0.01% 133
2025
Q2 		$4.61M Sell
10,358
-34
-0.3% -$15.7K 0.01% 130
2025
Q1 		$5.04M Hold
10,392
– – 0.01% 123
2024
Q4 		$4.18M Buy
+10,392
New +$4.82M 0.01% 129

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fayez Sarofim & Co's VRTX Position: Q1 2026 in Review

Fayez Sarofim & Co held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 10,000 shares worth $4.47M. The position accounts for 0.01% of the portfolio, ranked #119.

Fayez Sarofim & Co first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.04M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Fayez Sarofim & Co held 10,000 shares of Vertex Pharmaceuticals worth $4.47M as of Q1 2026.
  • Fayez Sarofim & Co left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.01% of Fayez Sarofim & Co's portfolio in Q1 2026, its #119 holding.
  • Fayez Sarofim & Co first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Fayez Sarofim & Co's Vertex Pharmaceuticals position peaked at $5.04M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fayez Sarofim & Co's 13F filing for Q1 2026, filed 15 May 2026.